Login
$OMCL
$34.56 -$0.47 (1.34%) Live

$OMCL 8-K SEC Filings

Filed On Filing
29 Oct 2026 8-K: Results of Operations and Financial Condition

Omnicell delivers solid third quarter 2026 financial results

30 Jul 2026 8-K: Results of Operations and Financial Condition

Omnicell delivers solid second quarter 2026 financial results

01 Jul 2026 8-K: Departure/Election of Directors or Officers; Compensation

Njoku continues to lead global operations and advance Omnicell's innovation and AI platform strategy; Randall Lipps continues to serve as Chief Executive Officer and Chairman of the Board

26 May 2026 8-K: Departure/Election of Directors or Officers; Compensation; Amendments to Articles/Bylaws; Change in Fiscal Year +1 more

AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF OMNICELL, INC.

28 Apr 2026 8-K: Results of Operations and Financial Condition

Omnicell delivers strong first quarter 2026 financial results

05 Feb 2026 8-K: Results of Operations and Financial Condition

Omnicell delivers solid fourth quarter 2025 financial results

08 Dec 2025 8-K: Regulation FD Disclosure

Announcing Omnicell Titan XT, the Next Generation, Automated Dispensing System Designed to Empower Autonomous Medication Management

30 Oct 2025 8-K: Results of Operations and Financial Condition

Results exceed previously issued third quarter 2025 guidance on all metrics

06 Oct 2025 8-K: Amendments to Articles/Bylaws; Change in Fiscal Year

Section 1. Registered Office. The registered office of the corporation in the State of Delaware shall be in the City of Wilmington, County of New Castle.

25 Aug 2025 8-K: Departure/Election of Directors or Officers; Compensation

Seasoned leader brings more than 30 years of experience driving growth for healthcare and technology companies

31 Jul 2025 8-K: Results of Operations and Financial Condition

Results exceed previously issued second quarter 2025 guidance for revenues, non-GAAP EBITDA and non-GAAP EPS

05 Jun 2025 8-K: Departure/Election of Directors or Officers; Compensation

This Separation Agreement and General Release (“Agreement”) is made by and between Omnicell, Inc., (“Company”) and the employee signatory below (“you” or “Employee,” together with Company, “Parties”). This Agreement is binding upon your ...

23 May 2025 8-K: Departure/Election of Directors or Officers; Compensation; Submission of Matters to a Vote of Security Holders

As described below under Item 5.07 of this Current Report on Form 8-K, at the 2025 Annual Meeting of Stockholders of Omnicell, Inc. (the “Company”) held on May 21, 2025 (the “Annual Meeting”), the Company’s stockholders approved an amend...

22 May 2025 8-K: Regulation FD Disclosure

Omnicell Expects Improved Profitability, Updates Second Quarter and Full Year 2025 Profit Outlook and Announces a New Stock Repurchase Program

06 May 2025 8-K: Results of Operations and Financial Condition

Results exceed previously issued first quarter 2025 guidance for total revenues and non-GAAP EPS

12 Mar 2025 8-K: Departure/Election of Directors or Officers; Compensation; Regulation FD Disclosure

FORT WORTH, Texas – March 12, 2025 -- Omnicell, Inc. (NASDAQ:OMCL) (“Omnicell,” “we,” “our,” “us,” “management,” or the “Company”), a leader in transforming the pharmacy and nursing care delivery model, today announced that Nchacha Etta ...

04 Mar 2025 8-K: Departure/Election of Directors or Officers; Compensation

This Employment Agreement (this “Agreement”) is entered into effective as of the 4th day of March, 2025 by and between Omnicell, Inc. and Randall A. Lipps (“Executive”). Unless the context indicates otherwise, the term “Company” means an...

06 Feb 2025 8-K: Results of Operations and Financial Condition

Results exceed previously issued full year guidance for bookings, total revenues, and non-GAAP EBITDA

25 Nov 2024 8-K: Entry into a Material Definitive Agreement; Creation of a Direct Financial Obligation +2 more

INDENTURE dated as of November 22, 2024 between OMNICELL, INC., a Delaware corporation, as issuer (the “Company,” as more fully set forth in ‎Section 1.01) and U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION, a national banking association...

18 Nov 2024 8-K: Entry into a Material Definitive Agreement; Other Events

THIS FIRST AMENDMENT TO SECOND AMENDED AND RESTATED CREDIT AGREEMENT (this “First Amendment”), dated as of November 18, 2024, is entered into by and among OMNICELL, INC., a Delaware corporation (the “Borrower”), each Lender party hereto,...

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support